Stay updated on SMT-NK with Pembrolizumab in Biliary Tract Cancer Clinical Trial
Sign up to get notified when there's something new on the SMT-NK with Pembrolizumab in Biliary Tract Cancer Clinical Trial page.

Latest updates to the SMT-NK with Pembrolizumab in Biliary Tract Cancer Clinical Trial page
- Check2 days agoChange DetectedRevision tag updated from v3.4.2 to v3.4.3. It appears to be an internal version update and does not alter the study details or page content.SummaryDifference0.1%

- Check10 days agoNo Change Detected
- Check17 days agoNo Change Detected
- Check24 days agoChange DetectedThe page revision updated to v3.4.2 from v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check31 days agoChange DetectedRevision updated from v3.4.0 to v3.4.1 with no visible changes to study content, eligibility criteria, or results; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check46 days agoChange DetectedGlossary UI options (Show glossary / Hide glossary) were added. Metadata lines were updated to include Last Update Submitted that Met QC Criteria, No FEAR Act Data, and Revision: v3.4.0, while the older QC-related entry and Revision: v3.3.4 were removed.SummaryDifference0.4%

- Check53 days agoChange DetectedAdded Revision: v3.3.4; Deleted Revision: v3.3.3. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check81 days agoChange DetectedAdded a footer note 'Revision: v3.3.3'; removed 'HHS Vulnerability Disclosure' and 'Revision: v3.3.2' from the footer.SummaryDifference0.1%

Stay in the know with updates to SMT-NK with Pembrolizumab in Biliary Tract Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SMT-NK with Pembrolizumab in Biliary Tract Cancer Clinical Trial page.